Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
21.62
+0.22 (1.03%)
At close: Mar 4, 2026, 4:00 PM EST
21.71
+0.09 (0.42%)
After-hours: Mar 4, 2026, 7:50 PM EST
Syndax Pharmaceuticals Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Syndax Pharmaceuticals stock have an average target of 80.69, with a low estimate of 17 and a high estimate of 600. The average target predicts an increase of 273.22% from the current stock price of 21.62.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Syndax Pharmaceuticals stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 8 | 8 | 8 | 8 | 8 |
| Buy | 1 | 3 | 3 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $51 → $57 | Strong Buy | Maintains | $51 → $57 | +163.64% | Mar 2, 2026 |
| Mizuho | Mizuho | Buy Maintains $410 → $600 | Buy | Maintains | $410 → $600 | +2,675.21% | Jan 27, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $56 | Strong Buy | Reiterates | $56 | +159.02% | Dec 9, 2025 |
| Barclays | Barclays | Buy Maintains $22 → $35 | Buy | Maintains | $22 → $35 | +61.89% | Nov 24, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $40 → $33 | Buy | Maintains | $40 → $33 | +52.64% | Nov 12, 2025 |
Financial Forecast
Revenue This Year
368.01M
from 172.35M
Increased by 113.52%
Revenue Next Year
561.18M
from 368.01M
Increased by 52.49%
EPS This Year
-1.60
from -3.29
EPS Next Year
-0.18
from -1.60
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 475.6M | 955.5M | |||
| Avg | 368.0M | 561.2M | |||
| Low | 231.3M | 293.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 175.9% | 159.6% | |||
| Avg | 113.5% | 52.5% | |||
| Low | 34.2% | -20.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.55 | 1.27 | |||
| Avg | -1.60 | -0.18 | |||
| Low | -2.78 | -1.94 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.